eligibility_summary
Inclusion: B‑cell NHL. Part 1: R/R, no better approved options, evaluable/measurable. Part 2: DLBCL/high‑grade or transformed after 1 prior regimen, measurable. ECOG 0–2. Adequate hematology without recent support. Negative pregnancy tests. Exclusion: active CNS, solid‑organ tx, prior JNJ‑80948543/75348780/87801493 or hypersensitivity, recent anticancer tx (≤2 wks/5 t½, CPI ≤6 wks), other cancer ≤1 yr, autoimmune on systemic immunosuppression ≤1 yr, infection ≤7 d, cardiac dysfunction.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06139406 (Phase 1) in relapsed/refractory B‑cell NHL. Interventions: • JNJ‑87801493 (SC). Investigational immunotherapy, specific mechanism not disclosed in the registry. Tested in combination with T‑cell engagers. • JNJ‑80948543 or JNJ‑75348780 (SC). CD3 T‑cell engager bispecific antibodies that bind CD3 on T cells and an unspecified B‑cell tumor antigen, redirecting cytotoxic T cells to kill malignant B cells. Mechanisms of action: • T‑cell engagers: form an immune synapse between T cells (via CD3) and B‑cell lymphoma cells (via a B‑cell antigen), triggering TCR/CD3 signaling, T‑cell activation, and perforin/granzyme‑mediated tumor cell lysis, may induce cytokine signaling. • JNJ‑87801493: mechanism not specified, evaluated to define a recommended phase 2 regimen in combination with TCEs. Targets/cells/pathways: CD3 on T cells, B‑cell lineage antigens on NHL cells (antigen not specified), T‑cell activation and cytotoxic pathways, tumor–immune synapse/cytokine pathways.